Because BCR-ABL inhibitor-treated CML cells released more IPP (Supplementary Fig. 2B), we postulated that their co-culture with γδT could promote γδT proliferation. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.